Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25102304 | 0.81 | ALDH1A1 (0.36) | ALDH1A1CYP2D6CYP2C19HSD17B10LMNA | |
| SCHEMBL6755726 | 0.77 | ALDH1A1 (0.40) | ALDH1A1CYP2D6CYP2C19HSD17B10LMNA | |
| SCHEMBL172743 | 0.77 | ALDH1A1 (0.40) | ALDH1A1CYP2D6CYP2C19HSD17B10LMNA | |
| SCHEMBL19841251 | 0.77 | ALDH1A1 (0.40) | ALDH1A1CYP2D6CYP2C19HSD17B10LMNA | |
| SCHEMBL19882464 | 0.72 | CYP2D6 (0.38) | ALDH1A1CYP2D6CYP2C19HSD17B10LMNA | |
| SCHEMBL22843 | 0.70 | ALDH1A1 (0.36) | ALDH1A1CYP2D6CYP2C19HSD17B10LMNA | |
| SCHEMBL2455143 | 0.70 | ALDH1A1 (0.36) | ALDH1A1CYP2D6CYP2C19HSD17B10LMNA | |
| SCHEMBL23340999 | 0.70 | SLC6A2 (0.33) | SLC6A4 | |
| SCHEMBL24952291 | 0.70 | ALDH1A1 (0.36) | ALDH1A1CYP2D6CYP2C19HSD17B10LMNA | |
| SCHEMBL3748741 | 0.67 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | NOVARTIS AG (CH) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | ZC3HAV1, TYMP, ZC3HAV1L | ALDH1A1 1776/4885CYP2D6 491/4885CYP2C19 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.